8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 24, 2026·SEC
TELA Bio, Inc.(TELA)Earnings, Financials & Key Ratios
TELA•NASDAQ
Price updated Jun 19, 2026
AboutTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Show more
- Revenue$80M+15.8%
- EBITDA-$34M-2.0%
- Net Income-$39M-2.6%
- EPS (Diluted)-0.83+37.6%
- Gross Margin67.69%+0.9%
- EBITDA Margin-42.05%+12.0%
- Operating Margin-42.05%+14.6%
- Net Margin-48.37%+11.4%
- ROE-223.35%-39.7%
TELA Key Insights
TELA Bio, Inc. (TELA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 34.5%
✗Weaknesses
- ✗High debt to equity ratio of 8.8x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 64.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TELA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TELA Price & Volume
TELA Bio, Inc. (TELA) stock price & volume — 10-year historical chart
Loading chart...
TELA Growth Metrics
TELA Bio, Inc. (TELA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years34.54%
3 Years24.68%
TTM13.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM43.97%
Return on Capital
10 Years-76.72%
5 Years-58.85%
3 Years-58.99%
Last Year-49.94%
TELA Recent Earnings
TELA Bio, Inc. (TELA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.21-50.0%
$0.14
Rev
$19M+2.5%
$19M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
$21M-0.8%
$21M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
$21M-1.7%
$21M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.22-22.2%
$0.18
Rev
$20M-8.8%
$22M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.21vs $0.14-50.0% | $19Mvs $19M+2.5% |
| Q2 2026 | Mar 25, 2026 | $0.16vs $0.18+11.1% | $21Mvs $21M-0.8% |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.17-11.8% | $21Mvs $21M-1.7% |
| Q3 2025 | Aug 11, 2025 | $0.22vs $0.18-22.2% | $20Mvs $22M-8.8% |
Based on last 12 quarters of dataView full earnings history →
TELA Peer Comparison
TELA Bio, Inc. (TELA) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 | |
 AHCO | 1.31B | 9.65 | -18.56 | -0.49% | -2.78% | -5.09% | 1.25 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% |
Compare TELA vs Peers
TELA Bio, Inc. (TELA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TELA Income Statement
TELA Bio, Inc. (TELA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.25M | 8.27M | 15.45M | 18.21M | 29.46M | 41.42M | 58.45M | 69.3M | 80.28M | 80.81M |
Revenue Growth % | - | 94.91% | 86.68% | 17.91% | 61.77% | 40.58% | 41.13% | 18.56% | 15.84% | 13.48% |
Cost of Goods Sold | 1.71M | 5.33M | 6.17M | 6.98M | 10.65M | 14.37M | 18.34M | 22.81M | 25.93M | 26.46M |
COGS % of Revenue | 40.35% | 64.44% | 39.97% | 38.32% | 36.15% | 34.7% | 31.38% | 32.92% | 32.31% | - |
Gross Profit | 2.53M▲ 0% | 2.94M▲ 16.2% | 9.27M▲ 215.2% | 11.23M▲ 21.2% | 18.81M▲ 67.5% | 27.04M▲ 43.8% | 40.11M▲ 48.3% | 46.49M▲ 15.9% | 54.34M▲ 16.9% | 54.35M▲ 0% |
Gross Margin % | 59.65% | 35.56% | 60.03% | 61.68% | 63.85% | 65.3% | 68.62% | 67.08% | 67.69% | 67.25% |
Gross Profit Growth % | - | 16.19% | 215.16% | 21.16% | 67.46% | 43.75% | 48.32% | 15.9% | 16.89% | - |
Operating Expenses | 19.46M | 22.88M | 28.43M | 36.51M | 48.26M | 66.05M | 84.19M | 80.6M | 88.1M | 88.16M |
OpEx % of Revenue | 458.33% | 276.58% | 184.09% | 200.46% | 163.81% | 159.47% | 144.03% | 116.31% | 109.74% | - |
Selling, General & Admin | 13.67M | 18.55M | 24.28M | 32.25M | 41.52M | 57.11M | 74.57M | 79.37M | 78.88M | 79.14M |
SG&A % of Revenue | 322.03% | 224.14% | 157.21% | 177.09% | 140.93% | 137.9% | 127.57% | 114.53% | 98.26% | - |
Research & Development | 5.79M | 4.34M | 4.15M | 4.25M | 6.74M | 8.94M | 9.62M | 8.81M | 9.22M | 9.02M |
R&D % of Revenue | 136.3% | 52.44% | 26.87% | 23.36% | 22.89% | 21.58% | 16.46% | 12.72% | 11.49% | - |
Other Operating Expenses | 94K | 70K | 0 | 0 | 0 | 0 | 0 | -7.58M | 0 | 0 |
Operating Income | -16.92M▲ 0% | -17.78M▼ 5.1% | -19.16M▼ 7.8% | -25.27M▼ 31.9% | -29.45M▼ 16.5% | -39.01M▼ 32.4% | -44.08M▼ 13.0% | -34.12M▲ 22.6% | -33.76M▲ 1.1% | -33.81M▲ 0% |
Operating Margin % | -398.68% | -214.91% | -124.06% | -138.77% | -99.96% | -94.18% | -75.4% | -49.23% | -42.05% | -41.84% |
Operating Income Growth % | - | -5.07% | -7.76% | -31.9% | -16.52% | -32.45% | -12.99% | 22.6% | 1.06% | - |
EBITDA | -16.16M | -16.53M | -18.58M | -24.75M | -28.92M | -37.82M | -43.27M | -33.1M | -33.76M | -33.29M |
EBITDA Margin % | -380.75% | -199.83% | -120.29% | -135.89% | -98.14% | -91.31% | -74.02% | -47.77% | -42.05% | -41.19% |
EBITDA Growth % | - | -2.3% | -12.37% | -33.21% | -16.83% | -30.79% | -14.4% | 23.49% | -1.97% | 14.01% |
D&A (Non-Cash Add-back) | 761K | 1.25M | 582K | 525K | 535K | 1.19M | 808K | 1.01M | 0 | 518K |
EBIT | -16.78M | -19.29M | -18.82M | -25.23M | -29.68M | -40.24M | -41.44M | -32.7M | -33.76M | -33.28M |
Net Interest Income | -4.56M | -1.8M | -3.61M | -3.56M | -3.6M | -4.05M | -5.22M | -5.29M | -5.25M | -1.97M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 4.56M | 1.8M | 3.61M | 3.56M | 3.6M | 4.05M | 5.22M | 5.29M | 5.25M | 1.97M |
Other Income/Expense | -4.41M | -3.31M | -3.26M | -3.52M | -3.83M | -5.29M | -2.59M | -3.87M | -4.85M | -5.79M |
Pretax Income | -21.33M▲ 0% | -21.09M▲ 1.1% | -22.43M▼ 6.3% | -28.79M▼ 28.4% | -33.28M▼ 15.6% | -44.3M▼ 33.1% | -46.66M▼ 5.3% | -37.98M▲ 18.6% | -38.6M▼ 1.6% | -39.6M▲ 0% |
Pretax Margin % | -502.57% | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.81% | -48.09% | -49% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -144K | 230K | 238K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.38% | -0.6% | -0.6% |
Net Income | -21.33M▲ 0% | -21.09M▲ 1.1% | -22.43M▼ 6.3% | -28.79M▼ 28.4% | -33.28M▼ 15.6% | -44.3M▼ 33.1% | -46.66M▼ 5.3% | -37.84M▲ 18.9% | -38.83M▼ 2.6% | -39.84M▲ 0% |
Net Margin % | -502.57% | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.6% | -48.37% | -49.3% |
Net Income Growth % | - | 1.13% | -6.32% | -28.4% | -15.57% | -33.12% | -5.35% | 18.91% | -2.62% | 8.3% |
Net Income (Continuing) | -21.33M | -21.09M | -22.43M | -28.79M | -33.28M | -44.3M | -46.66M | -37.84M | -38.83M | -39.84M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.29▲ 0% | -3.25▲ 1.2% | -2.26▲ 30.5% | -2.23▲ 1.3% | -2.30▼ 3.1% | -2.73▼ 18.7% | -2.04▲ 25.3% | -1.33▲ 34.8% | -0.83▲ 37.6% | -0.70▲ 0% |
EPS Growth % | - | 1.22% | 30.46% | 1.33% | -3.14% | -18.7% | 25.27% | 34.8% | 37.59% | 43.97% |
EPS (Basic) | -3.29 | -3.25 | -2.26 | -2.23 | -2.30 | -2.73 | -2.04 | -1.33 | -0.83 | - |
Diluted Shares Outstanding | 6.49M | 6.49M | 11.41M | 12.93M | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M | 57.26M |
Basic Shares Outstanding | 6.49M | 6.49M | 11.41M | 12.93M | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M | 57.26M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TELA Balance Sheet
TELA Bio, Inc. (TELA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.35M | 23.25M | 64.33M | 83.22M | 59.05M | 62.45M | 71.73M | 78.07M | 75.58M | 64.3M |
Cash & Short-Term Investments | 11.35M | 17.28M | 54.59M | 74.39M | 43.93M | 42.02M | 46.73M | 52.67M | 50.84M | 39.54M |
Cash Only | 11.35M | 17.28M | 45.3M | 74.39M | 43.93M | 42.02M | 46.73M | 52.67M | 50.84M | 39.54M |
Short-Term Investments | 0 | 0 | 9.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 757K | 1.3M | 2.84M | 2.68M | 4.23M | 6.62M | 9.74M | 10.1M | 10.35M | 9.71M |
Days Sales Outstanding | 65.09 | 57.26 | 67.02 | 53.77 | 52.45 | 58.35 | 60.8 | 53.19 | 47.05 | 51.68 |
Inventory | 1.81M | 4.35M | 4.6M | 3.91M | 7.66M | 11.79M | 13.16M | 12.78M | 11.02M | 12.21M |
Days Inventory Outstanding | 386.73 | 297.64 | 272.12 | 204.34 | 262.46 | 299.44 | 261.93 | 204.5 | 155.04 | 159.15 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 2.02M | 2.1M | 2.52M | 3.37M | 2.83M |
Total Non-Current Assets | 1.19M | 3.97M | 3.59M | 3.23M | 3.49M | 5.41M | 6.32M | 9.25M | 5.84M | 5.59M |
Property, Plant & Equipment | 1.16M | 758K | 677K | 626K | 1.19M | 2.91M | 3.94M | 4.08M | 3.73M | 3.6M |
Fixed Asset Turnover | 3.66x | 10.92x | 22.82x | 29.09x | 24.84x | 14.24x | 14.84x | 16.99x | 21.53x | 21.72x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 3.21M | 2.91M | 2.61M | 2.3M | 2.5M | 2.12M | 1.74M | 1.36M | 1.26M |
Long-Term Investments | 24K | 0 | 0 | 0 | 0 | 0 | 265K | 2.54M | 250K | 1.9M |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500K | 726K |
Total Assets | 15.53M▲ 0% | 27.23M▲ 75.3% | 67.92M▲ 149.5% | 86.46M▲ 27.3% | 62.54M▼ 27.7% | 67.86M▲ 8.5% | 78.05M▲ 15.0% | 87.33M▲ 11.9% | 81.42M▼ 6.8% | 69.89M▲ 0% |
Asset Turnover | 0.27x | 0.30x | 0.23x | 0.21x | 0.47x | 0.61x | 0.75x | 0.79x | 0.99x | 1.15x |
Asset Growth % | - | 75.3% | 149.47% | 27.29% | -27.66% | 8.49% | 15.02% | 11.89% | -6.77% | 12.05% |
Total Current Liabilities | 6.15M | 9.56M | 6.71M | 6.61M | 10.57M | 12.4M | 16.97M | 15.6M | 17.98M | 17.83M |
Accounts Payable | 1.51M | 3.42M | 3.17M | 652K | 2.41M | 1.53M | 1.67M | 2.15M | 2.31M | 3.89M |
Days Payables Outstanding | 321.11 | 234.18 | 187.47 | 34.1 | 82.73 | 38.95 | 33.17 | 34.35 | 32.5 | 35.57 |
Short-Term Debt | 905K | 0 | 0 | 0 | 0 | 340K | 565K | 545K | 0 | 0 |
Deferred Revenue (Current) | 1.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.94M | 985K | 1.19M | 2.24M | 3.15M | 4.11M | 5.52M | 5.56M | 15.67M | 13.94M |
Current Ratio | 2.33x | 2.43x | 9.58x | 12.60x | 5.58x | 5.03x | 4.23x | 5.01x | 4.20x | 3.61x |
Quick Ratio | 2.04x | 1.98x | 8.90x | 12.01x | 4.86x | 4.08x | 3.45x | 4.19x | 3.59x | 2.92x |
Cash Conversion Cycle | 130.72 | 120.72 | 151.67 | 224 | 232.18 | 318.83 | 289.56 | 223.33 | 169.59 | 175.26 |
Total Non-Current Liabilities | 117.56M | 155.53M | 30.25M | 30.83M | 31.87M | 41.15M | 42.2M | 43.27M | 57.13M | 57.26M |
Long-Term Debt | 3.61M | 29.73M | 30.24M | 30.83M | 31.49M | 39.92M | 40.52M | 41.12M | 55.65M | 55.87M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.2M | 1.69M | 1.39M | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 756K | 0 | 0 |
Other Non-Current Liabilities | 113.94M | 125.8M | 4K | 0 | 380K | 31K | 0 | 0 | 1.48M | 1.39M |
Total Liabilities | 123.7M | 165.09M | 36.96M | 37.43M | 42.45M | 53.55M | 59.17M | 58.87M | 75.11M | 75.09M |
Total Debt | 4.51M | 29.73M | 30.24M | 30.83M | 31.49M | 41.46M | 42.77M | 43.06M | 55.65M | 55.87M |
Net Debt | -6.83M | 12.46M | -15.06M | -43.57M | -12.44M | -563K | -3.96M | -9.61M | 4.81M | 16.32M |
Debt / Equity | - | - | 0.98x | 0.63x | 1.57x | 2.90x | 2.26x | 1.51x | 8.82x | -10.74x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.68x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.49x |
Interest Coverage | -3.68x | -10.70x | -5.21x | -7.08x | -8.25x | -9.93x | -7.93x | -6.18x | -6.44x | -16.87x |
Total Equity | -108.17M▲ 0% | -137.86M▼ 27.4% | 30.96M▲ 122.5% | 49.03M▲ 58.3% | 20.1M▼ 59.0% | 14.3M▼ 28.8% | 18.88M▲ 32.0% | 28.46M▲ 50.7% | 6.31M▼ 77.8% | -5.2M▲ 0% |
Equity Growth % | - | -27.45% | 122.46% | 58.34% | -59.01% | -28.82% | 31.99% | 50.72% | -77.82% | 138.31% |
Book Value per Share | -16.67 | -21.25 | 2.71 | 3.79 | 1.39 | 0.88 | 0.83 | 1.00 | 0.13 | -0.09 |
Total Shareholders' Equity | -108.17M | -137.86M | 30.96M | 49.03M | 20.1M | 14.3M | 18.88M | 28.46M | 6.31M | -5.2M |
Common Stock | 7K | 0 | 11K | 14K | 15K | 19K | 24K | 39K | 44K | 45K |
Retained Earnings | -108.17M | -137.86M | -167.86M | -196.65M | -229.93M | -274.23M | -320.89M | -358.73M | -397.56M | -409.83M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.79M | -3.24M | -19K | -71K | -52K | 150K | 91K | 90K | 91K | 85K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TELA Cash Flow Statement
TELA Bio, Inc. (TELA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.37M | -19.92M | -25.52M | -24.46M | -30.43M | -40.75M | -40.86M | -41.59M | -28.22M | -29.66M |
Operating CF Margin % | -385.58% | -240.8% | -165.24% | -134.28% | -103.29% | -98.38% | -69.9% | -60.02% | -35.15% | - |
Operating CF Growth % | - | -21.73% | -28.1% | 4.18% | -24.44% | -33.9% | -0.27% | -1.81% | 32.16% | 82.91% |
Net Income | -21.33M | -21.09M | -22.43M | -28.79M | -33.28M | -44.3M | -46.66M | -37.84M | -38.83M | -39.84M |
Depreciation & Amortization | 761K | 1.25M | 582K | 525K | 535K | 1.19M | 808K | 1.01M | 1.01M | 743K |
Stock-Based Compensation | 197K | 216K | 457K | 2.06M | 3.66M | 3.99M | 5.03M | 4.36M | 3.8M | 1.8M |
Deferred Taxes | -40K | 1.22M | 5K | 0 | 14K | 0 | 0 | -144K | 230K | 178K |
Other Non-Cash Items | 3.97M | 2.94M | 2.09M | 1.84M | 2.1M | 4.13M | 1.64M | -4.12M | 4.08M | 6.59M |
Working Capital Changes | 75K | -4.46M | -6.24M | -86K | -3.47M | -5.76M | -1.67M | -4.87M | 1.5M | 869K |
Change in Receivables | -578K | -541K | -1.53M | 149K | -1.55M | -2.42M | -3.06M | -762K | -110K | 885K |
Change in Inventory | -127K | -4.76M | -1.84M | -620K | -5.19M | -6.07M | -2.72M | -2.97M | -503K | -1.31M |
Change in Payables | -748K | 1.91M | -773K | -2M | 1.6M | -884K | 11K | 482K | 141K | -119K |
Cash from Investing | -101K | -1.56M | -11.98M | 9.12M | -627K | -1.87M | -599K | 4.45M | 846K | 898K |
Capital Expenditures | -114K | -1.56M | -2.7M | -167K | -627K | -872K | -611K | 0 | -448K | -535K |
CapEx % of Revenue | 2.69% | 18.88% | 17.46% | 0.92% | 2.13% | 2.11% | 1.05% | 1.43% | 0.56% | 0.66% |
Acquisitions | 13K | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 1.29M | 1.11M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 13K | 4K | 0 | 0 | 0 | -1M | 12K | 4.45M | 0 | 318K |
Cash from Financing | 26.34M | 27.41M | 65.53M | 44.41M | 585K | 40.85M | 46.27M | 43.06M | 25.75M | 25.57M |
Debt Issued (Net) | 12.2M | 25M | 0 | 0 | 0 | 10M | 0 | 0 | 14.03M | 14.03M |
Equity Issued (Net) | 0 | 3.98M | 65.52M | 44.72M | 585K | 34.4M | 46.34M | 42.92M | 11.93M | 11.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 105K | -3K |
Other Financing | 14.14M | -1.56M | 14K | -313K | 0 | -3.55M | -74K | 138K | -205K | -351K |
Net Change in Cash | 9.87M▲ 0% | 5.93M▼ 39.9% | 28.02M▲ 372.4% | 29.09M▲ 3.8% | -30.46M▼ 204.7% | -1.91M▲ 93.7% | 4.97M▲ 360.2% | 5.94M▲ 19.4% | -1.84M▼ 131.0% | -3.29M▲ 0% |
Free Cash Flow | -16.48M▲ 0% | -21.49M▼ 30.4% | -28.22M▼ 31.3% | -24.62M▲ 12.7% | -31.06M▼ 26.1% | -42.62M▼ 37.2% | -41.47M▲ 2.7% | -42.58M▼ 2.7% | -28.67M▲ 32.7% | -30.2M▲ 0% |
FCF Margin % | -388.27% | -259.68% | -182.7% | -135.19% | -105.42% | -102.9% | -70.94% | -61.45% | -35.71% | -37.37% |
FCF Growth % | - | -30.36% | -31.34% | 12.75% | -26.14% | -37.22% | 2.7% | -2.69% | 32.68% | 19.8% |
FCF per Share | -2.54 | -3.31 | -2.47 | -1.90 | -2.15 | -2.62 | -1.81 | -1.49 | -0.61 | -0.53 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.94x | 1.14x | 0.85x | 0.91x | 0.92x | 0.88x | 1.10x | 0.73x | 0.76x |
Interest Paid | 0 | 0 | 0 | 2.98M | 0 | 3.39M | 4.62M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TELA Key Ratios
TELA Bio, Inc. (TELA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -72.43% | -72% | -96.28% | -257.51% | -281.23% | -159.87% | -223.35% | -1344.47% |
Return on Invested Capital (ROIC) | - | - | -177.48% | -336.79% | -273.41% | -230.69% | -151.56% | -168.96% | -194.26% |
Gross Margin | 35.56% | 60.03% | 61.68% | 63.85% | 65.3% | 68.62% | 67.08% | 67.69% | 67.25% |
Net Margin | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.6% | -48.37% | -49.3% |
Debt / Equity | - | 0.98x | 0.63x | 1.57x | 2.90x | 2.26x | 1.51x | 8.82x | -10.74x |
Interest Coverage | -10.70x | -5.21x | -7.08x | -8.25x | -9.93x | -7.93x | -6.18x | -6.44x | -16.87x |
FCF Conversion | 0.94x | 1.14x | 0.85x | 0.91x | 0.92x | 0.88x | 1.10x | 0.73x | 0.76x |
Revenue Growth | 94.91% | 86.68% | 17.91% | 61.77% | 40.58% | 41.13% | 18.56% | 15.84% | 13.48% |
Related:TELA Dividend History·TELA Revenue History·TELA Price History·TELA P/E History·TELA Financial Ratios·TELA Institutional Holders
TELA SEC Filings & Documents
TELA Bio, Inc. (TELA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TELA Frequently Asked Questions
TELA Bio, Inc. (TELA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TELA Bio, Inc. (TELA) reported $80.8M in revenue for fiscal year 2025. This represents a 1804% increase from $4.2M in 2017.
TELA Bio, Inc. (TELA) grew revenue by 15.8% over the past year. This is strong growth.
TELA Bio, Inc. (TELA) reported a net loss of $39.8M for fiscal year 2025.
Dividend & Returns
TELA Bio, Inc. (TELA) has a return on equity (ROE) of -223.4%. Negative ROE indicates the company is unprofitable.
TELA Bio, Inc. (TELA) had negative free cash flow of $30.2M in fiscal year 2025, likely due to heavy capital investments.